Health Care • Biotechnology: Pharmaceutical Preparations
$97.56 ▲ +2.38
(+2.50%)
MKT CAP: $7.67B • VOL: 1.38M
52W L $37 52W H $98
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$82
MEDIAN
$109
MEAN
$111
HIGH
$133
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE KNSA TAPE
KNSA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $118.05 | $112.19 | 2025-02-14 | $88.78 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $122.93 | $115.12 | 2025-02-06 | $91.71 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $111.22 | $107.32 | 2025-01-29 | $93.66 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $99.51 | — | 2025-01-17 | $95.61 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $85.85 | $92.68 | 2025-01-09 | $86.83 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $116.10 | $101.46 | 2024-12-18 | $84.88 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $94.63 | $98.54 | 2024-12-04 | $90.73 | -4.3% | 48% | C |